Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 341-348

  Quiros Roldan, Eugenia ^a   Calabresi, Alessandra ^a   Lapadula, Giuseppe ^a   Tirelli, Valeria ^a   Costarelli, Silvia ^a   Cologni, Giuliana ^a   Zaltron, Serena ^a   Puoti, Massimo ^a   Carosi, Giampiero ^a   Torti, Carlo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MEMBRANE ANTIGEN; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADD ON THERAPY; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MALE; MIXED INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS MUTANT; ANTIVIRAL RESISTANCE; BLOOD; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; IMMUNOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; TIME; TREATMENT OUTCOME; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TIME FACTORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 47249085228     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. New Engl J Med 2007; 356:1445-1454.
2. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-1847.
3. Lacombe K, Gozlan J, Boelle P-Y, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil. AIDS 2005; 19:907-915.
4. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43:548-555.
5. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20:1951-1954.
6. Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepatitis 2007; 14:176-182.
7. Jain MK, Opio CK, Osuagwn CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis 2007; 44:996-1000.
8. Germer J, Charlton M, Ishitani M, et al. Characterization of Hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant 2003; 3:743-753.
9. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. New Engl J Med 2006; 354:1807-1812.
10. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606.
11. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
12. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug resistant hepatitis B virus strain in a liver transplanted patient. Gastroenterology 2006; 131:1253-1261.
13. Lee KM, Kim YS, Ko YY, et al. Emergence of vaccine induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci 2001; 16:359-362.
14. Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24:173-181.
15. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870.
16. McMahon MA, Jilek BL, Brennan T, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. New Eng J Med 2007; 356:2614-2621.
17. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
18. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1649-1657.